Cytodyn IncOOTC CYDY Stock Report

CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. The company is headquartered in Vancouver Washington, Washington and currently employs 23 full-time employees. The company went IPO on 2005-11-17. Its CCR5 receptor is a protein located on the surface of various cells including white blood cells and cancer cells. Its clinical developments include human immunodeficiency virus (HIV), nonalcoholic steatohepatis (NASH) and solid tumors in oncology. In HIV, it focuses on the multi-drug resistant HIV population, creating a long-acting formulation of leronlimab, and HIV cure using adenovirus vectors. Its NASH focuses on the general population of those affected by NASH, and the subpopulation of patients with NASH and HIV. Its oncology product focuses on the combination therapy for solid tumors to explore the potential of leronlimab in the tumor microenvironment and the potential benefit for decreasing angiogenesis, potential macrophage repolarization, decreasing metastasis.